The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of ...